A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients ( e 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
This randomized phase III trial studies rituximab with bendamustine hydrochloride or
ibrutinib to see how well they work compared to ibrutinib alone in treating older patients
with previously untreated chronic lymphocytic leukemia. Monoclonal antibodies, such as
rituximab, may block cancer growth in different ways by targeting certain cells. Drugs used
in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the
growth of cancer cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Ibrutinib may stop the growth of cancer cells by blocking some
of the enzymes needed for cell growth. It is not yet known whether rituximab with
bendamustine hydrochloride is more effective than rituximab and ibrutinib or ibrutinib alone
in treating chronic lymphocytic leukemia.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.